BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:From transformative genetic therapies in rare diseases to neur oimmunology candidates addressing residual unmet needs in MS\, and novel target validation driving confidence in disease modification for neurodeg eneration\, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.\n\nReturning for its second year\, following the inaugural launch that attracted over 100 attendees\, the 2n d Neuroscience Innovation Partnering and Licensing Summit is strategicall y timed to facilitate multiple high-impact\, in-person meetings without t he distractions of a broader\, less focused setting.\n\nWho Attends This Differentiated Business Development Initiative?\n\n- Global Pharma: Heads of Business Development\, Search and Evaluation\, and Asset Scouting for Neuroscience - comparing pipelines and enabling technologies to fuel fut ure innovation.- Innovative Biotech: C-level executives and BD leaders ac ross neurodegeneration\, psychiatry\, neuro-oncology\, and pain - seeking feedback\, validation\, and strategic partnerships with pharma and inves tors.- Investors and Venture Capital: Leaders focused on neuroscience inv estments with higher risk appetite - looking for insights into pharma str ategy and access to breakthrough opportunities.\n\nLess competitive and m ore accessible\, pharma can assess related programs back-to-back\, while biotech has a protected opportunity to meet multiple big pharma players a gainst the backdrop of market intelligence.\n\nURLs:Website: \;https: //go.evvnt.com/3491403-0?pid=185Tickets: \;https://go.evvnt.com/34914 03-2?pid=185Brochure: \;https://go.evvnt.com/3491403-3?pid=185\n\nPri ces:Drug Developer Pricing - 2 Day Pass (Conference + 15 Min Presentation ): USD 6498.00\,Drug Developer - 1 Day Pass (Conference): USD 3099.00\,Ac ademic Pricing - 2 Day Pass (Conference + 15 Min Presentation): USD 5524. 00\,Academic Pricing - 1 Day Pass (Conference): USD 2699.00\n\nSpeakers:& nbsp\;Murali Gopalakrishnan\, Global Head\, Neuroscience Search and Evalu ation\, Corporate Strategy\, AbbVie\, Karen Harris\, Chief Financial Offi cer and Head of Mission Related Investing\, Alzheimer's Drug Discovery Fo undation\, Nicole Bjorklund\, Director - Research and Grants\, Associatio n for Frontotemporal Degeneration\, Annika Malmberg\, Api Development Hea d\, Biogen\, Catherine Abbadie\, External Innovation\, Biogen\, Mike Dial \, Managing Director\, Chugai Ventures\, Stephen Zicha\, Senior Director\ , Neuroscience\, Eli Lilly\, Lauren Mifflin\, Principal\, Company Creatio n\, Frazier Life Sciences\, David Donabedian\, Executive Partner\, Longwo od Funds\, Chris Adams\, Head of Search and Evaluation Neuroscience\, Nov artis\, Laura Ripin\, Head of BD and L Transactions Neuroscience\, Novart is\, XiaoQian Liu\, Associate Director\, Business Development Search and Evaluation\, Otsuka\, Michaela Tolman\, Commercial Development Lead\, Pfi zer\, Vidya Nadar\, Director\, Sanofi\, Jonathan Behr\, Partner\, SV Deme ntia Discovery Fund\, Eleni Stavridi\, Head Search and Evaluation\, Neuro science\, Takeda\, Ross Gruber\, Neuroscience Search and Evaluation Lead\ , Takeda\, Julianna Sullivan\, Director of Research Alliances\, The Micha el J. Fox Foundation for Parkinson's Research\, Danielle Feldman\, Co-fou nder and Senior Director Corporate Development\, Aliada Therapeutics\, Ma rtin Jacko\, CEO\, Aperture Therapeutics\, Patrick Gallagher\, Chief Busi ness Officer and Head of the US\, Argo Biopharma\, Andrew Morris\, Vice P resident\, Business Development\, CAMP4 Therapeutics\, Arun Swaminathan\, Chief Executive Officer\, Coya Therapeutics\, Mathias Schmidt\, Executiv e Advisor JCR Pharmaceuticals\, John Mayfield\, CEO\, JEO Biotech Advisor s\, Michael Bowen\, Co-Founder and Chief Scientific Officer\, Kinoxis The rapeutics\, Revital Mandi Levin\, Chief Executive Officer and Founder\, N anocarry\, Jackie von Salm\, Co-Founder and Scientific Chief and Officer\ , Psilera\, Gerard Caelles\, Chief Business Officer\, Splice Bio\, Alice Zhang\, Chief Executive Officer and Co-Founder\, Verge Genomics\n\nCatego ry: \;Conferences | Science\, Health and Medicine | Pharmaceuticals\n \nDate and Time: \;28th April 2026 at 8:00 am to 29th April 2026 at 3 :00 pm\n DTEND:20260429T150000 DTSTAMP:20260512T214306Z DTSTART:20260428T080000 LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa chusetts\, 02116\, SEQUENCE:0 SUMMARY:From transformative genetic therapies in rare diseases to neuroimm unology candidates addressing residual unmet needs in MS\, and novel targ et valida... UID:c9e2babc-0ff4-4383-bca1-99db65c4e306 END:VEVENT END:VCALENDAR